West Pharmaceutical Services (WPS) Stock Statistics & Valuation Metrics
Total Valuation
West Pharmaceutical Services has a market cap or net worth of EUR 25.74B. The enterprise value is EUR 26.10B.
- Market Cap
- EUR 25.74B
- Enterprise Value
- EUR 26.10B
Share Statistics
West Pharmaceutical Services has 69,661,030 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 69,661,030
- Owned by Insiders
- 0.55%
- Owned by Institutions
- 62.51%
Financial Efficiency
West Pharmaceutical Services’s return on equity (ROE) is 0.16 and return on invested capital (ROIC) is 13.62%.
- Return on Equity (ROE)
- 0.16
- Return on Assets (ROA)
- 0.12
- Return on Invested Capital (ROIC)
- 13.62%
- Return on Capital Employed (ROCE)
- 0.17
- Revenue Per Employee
- 284.60K
- Profits Per Employee
- 45.71K
- Employee Count
- 10,800
- Asset Turnover
- 0.72
- Inventory Turnover
- 4.44
Valuation Ratios
The current PE Ratio of West Pharmaceutical Services is 46.00. West Pharmaceutical Services’s PEG ratio is 1.43.
- PE Ratio
- 46.00
- PS Ratio
- 8.46
- PB Ratio
- 9.79
- Price to FCF
- 63.40
- Price to Operating Cash Flow
- 44.38
- PEG Ratio
- 1.43
Income Statement
In the last 12 months, West Pharmaceutical Services had revenue of 3.07B and earned 493.70M in profits. Earnings per share was 6.83.
- Revenue
- 3.07B
- Gross Profit
- 1.10B
- Operating Income
- 617.40M
- Pretax Income
- 615.30M
- Net Income
- 493.70M
- EBITDA
- 770.60M
- Earnings Per Share (EPS)
- 6.83
Cash Flow
In the last 12 months, operating cash flow was 654.50M and capital expenditures -201.10M, giving a free cash flow of 453.40M billion.
- Operating Cash Flow
- 654.50M
- Free Cash Flow
- 453.40M
- Free Cash Flow per Share
- 6.44
Dividends & Yields
West Pharmaceutical Services pays an annual dividend of ―, resulting in a dividend yield of 0.20%
- Dividend Per Share
- ―
- Dividend Yield
- 0.20%
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 1.58%
- Earnings Yield
- 2.20%
Stock Price Statistics
- Beta
- 0.26
- 52-Week Price Change
- 56.41%
- 50-Day Moving Average
- 319.84
- 200-Day Moving Average
- 270.47
- Relative Strength Index (RSI)
- 83.15
- Average Volume (3m)
- 52
Important Dates
West Pharmaceutical Services upcoming earnings date is Feb 18, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Oct 29, 2026
- Next Earnings Date
- Feb 18, 2027
- Ex-Dividend Date
- ―
Financial Position
West Pharmaceutical Services as a current ratio of 3.02, with Debt / Equity ratio of 13.12%
- Current Ratio
- 3.02
- Quick Ratio
- 2.34
- Debt to Market Cap
- 0.02
- Net Debt to EBITDA
- -0.49
- Interest Coverage Ratio
- 1029.00
Taxes
In the past 12 months, West Pharmaceutical Services has paid 121.60M in taxes.
- Income Tax
- 121.60M
- Effective Tax Rate
- 0.20
Enterprise Valuation
West Pharmaceutical Services EV to EBITDA ratio is 29.56, with an EV/FCF ratio of 63.04.
- EV to Sales
- 8.42
- EV to EBITDA
- 29.56
- EV to Free Cash Flow
- 63.04
- EV to Operating Cash Flow
- 43.67
Balance Sheet
West Pharmaceutical Services has EUR 464.10M in cash and marketable securities with EUR 305.00M in debt, giving a net cash position of EUR 159.10M billion.
- Cash & Marketable Securities
- EUR 464.10M
- Total Debt
- EUR 305.00M
- Net Cash
- EUR 159.10M
- Net Cash Per Share
- EUR 2.28
- Tangible Book Value Per Share
- EUR 40.53
Margins
Gross margin is 37.59%, with operating margin of 22.97%, and net profit margin of 18.81%.
- Gross Margin
- 37.59%
- Operating Margin
- 22.97%
- Pretax Margin
- 23.36%
- Net Profit Margin
- 18.81%
- EBITDA Margin
- 28.47%
- EBIT Margin
- 23.06%
Analyst Forecast
The average price target for West Pharmaceutical Services is EUR 428.15, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- EUR 428.15
- Price Target Upside
- 12.55% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 6
- Revenue Growth Forecast
- 7.16%
- EPS Growth Forecast
- 26.22%
Scores
- Smart Score
- 7
- AI Score
- ―
